Sign up

Armistice Capital, LLC

$3.6B assets · 323 holdings · Q2 2026 · Filed 14 AUG 2026

About Armistice Capital, LLC’s 13F portfolio

Armistice Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Armistice Capital, LLC reported $3.6B across 323 US-listed positions (). Its largest position is MADRIGAL PHARMACEUTICALS INC (MDGL) at 4.3% of the reported book, and its ten biggest holdings make up 27% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$3.6B
Assets (13F)
#1,017
of 8,839 by size
323
Holdings
27%
Top-10 weight
239
Buys
161
Sells
Top holdings · Q2 2026
323 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: MDGL
MADRIGAL PHARMACEUTICALS INC
—
—
4.3%
288K$154.6M
2
NASDAQ: SUPN
SUPERNUS PHARMACEUTICALS
—
—
3.4%
2.6M$123.1M
3
NASDAQ: CYTK
CYTOKINETICS INC
—
—
2.8%
1.2M$102.3M
4
NASDAQ: INCY
INCYTE CORP
—
—
2.8%
900K$102.0M
5
NASDAQ: NBIX
NEUROCRINE BIOSCIENCES INC
—
—
2.5%
536K$90.3M
6
NASDAQ: TVTX
TRAVERE THERAPEUTICS INC
—
—
2.5%
1.6M$89.3M
7
NASDAQ: AGIO
AGIOS PHARMACEUTICALS INC
—
—
2.5%
2.4M$89.1M
8
NASDAQ: PTCT
PTC THERAPEUTICS INC
—
—
2.4%
1.1M$87.4M
9
NYSE: UNH
UNITEDHEALTH GROUP INC
—
—
2.1%
183K$76.1M
10
NASDAQ: FRPT
FRESHPET INC
—
—
2.1%
1.3M$74.5M
11
NASDAQ: DYN
DYNE THERAPEUTICS INC
—
—
1.9%
3.1M$68.6M
12
NASDAQ: AMZN
AMAZON COM INC
—
—
1.9%
285K$67.8M
13
NASDAQ: IMVT
IMMUNOVANT INC
—
—
1.9%
1.7M$66.9M
14
NASDAQ: RIGL
RIGEL PHARMACEUTICALS INC
—
—
1.8%
1.7M$65.4M
15
NYSE: TMO
THERMO FISHER SCIENTIFIC INC
—
—
1.7%
122K$61.4M
16
NASDAQ: IRWD
IRONWOOD PHARMACEUTICALS INC
—
—
1.6%
13.9M$58.7M
17
NASDAQ: HRMY
HARMONY BIOSCIENCES HLDGS IN
—
—
1.6%
1.6M$56.9M
18
NASDAQ: REGN
REGENERON PHARMACEUTICALS
—
—
1.5%
90K$56.0M
19
NASDAQ: NKTR
NEKTAR THERAPEUTICS
—
—
1.4%
724K$50.5M
20
NASDAQ: MLYS
MINERALYS THERAPEUTICS INC
—
—
1.3%
1.7M$46.8M
21
NASDAQ: SNY
SANOFI SA
—
—
1.3%
1.1M$45.4M
22
NASDAQ: IMCR
IMMUNOCORE HLDGS PLC
—
—
1.3%
1.4M$45.3M
23
NASDAQ: GOOGL
ALPHABET INC
—
—
1.3%
126K$45.2M
24
NASDAQ: SLDB
SOLID BIOSCIENCES INC
—
—
1.2%
4.3M$42.7M
25
NASDAQ: MDB
MONGODB INC
—
—
1.2%
125K$42.0M

Showing 1–25 of 323 positions on this page reported in this 13F.

Sector allocation
  • Healthcare68%
  • Technology15%
  • Consumer Cyclical7.7%
  • Communication Services4.2%
  • Consumer Defensive3.2%
  • Industrials1.2%
  • Financial Services0.1%
  • Real Estate0.1%
  • Basic Materials0.1%
  • Energy0.1%
  • Utilities0.0%
Recent activity · vs 2026-03-31
Bought239
  • AddedMDGLMADRIGAL PHARMACEUTICALS INC+8.9%$154.6M
  • AddedSUPNSUPERNUS PHARMACEUTICALS+39.6%$123.1M
  • AddedCYTKCYTOKINETICS INC+57.1%$102.3M
  • AddedINCYINCYTE CORP+37.0%$102.0M
  • AddedUNHUNITEDHEALTH GROUP INC+23.6%$76.1M
  • AddedFRPTFRESHPET INC+15.3%$74.5M
  • AddedAMZNAMAZON COM INC+8.6%$67.8M
  • AddedRIGLRIGEL PHARMACEUTICALS INC+30.6%$65.4M
  • AddedTMOTHERMO FISHER SCIENTIFIC INC+33.9%$61.4M
  • AddedREGNREGENERON PHARMACEUTICALS+149%$56.0M
Sold161
  • ReducedNBIXNEUROCRINE BIOSCIENCES INC−26.0%$90.3M
  • ReducedTVTXTRAVERE THERAPEUTICS INC−67.9%$89.3M
  • ReducedAGIOAGIOS PHARMACEUTICALS INC−11.6%$89.1M
  • ReducedPTCTPTC THERAPEUTICS INC−48.4%$87.4M
  • ReducedDYNDYNE THERAPEUTICS INC−2.8%$68.6M
  • ReducedIMVTIMMUNOVANT INC−51.3%$66.9M
  • ReducedIRWDIRONWOOD PHARMACEUTICALS INC−7.3%$58.7M
  • ReducedHRMYHARMONY BIOSCIENCES HLDGS IN−3.7%$56.9M
  • ReducedKURAKURA ONCOLOGY INC−1.6%$40.3M
  • ReducedUBERUBER TECHNOLOGIES INC−4.0%$35.9M
5%+ Beneficial Ownership Stakes · 46 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
—
Aridis Pharmaceuticals, Inc.
13G11.4% · 2 classes5.1MFiled 16 NOV 2026
2
REKR
Rekor Systems, Inc.
13G10.0%14.1MFiled 17 FEB 2026
3
CTOR
Citius Oncology, Inc.
13G10.0% · 2 classes9.4MFiled 16 NOV 2026
4
TMCI
TREACE MEDICAL CONCEPTS, INC.
13G10.0% · 2 classes6.4MFiled 17 FEB 2026
5
—
Li-Cycle Holdings Corp.
13G10.0% · 2 classes4.6MFiled 16 NOV 2026
6
IINN
INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
13G10.0%4.3MFiled 15 MAY 2026
7
CYAB
Cyabra, Inc.
13G10.0%3.9MFiled 16 NOV 2026
8
ALBT
Change Agents Corporation
13G10.0%1.6MFiled 14 AUG 2026
9
LTRN
Lantern Pharma Inc.
13G10.0%1.5MFiled 16 NOV 2026
10
GOVX
GEOVAX LABS, INC.
13G10.0% · 2 classes1.3MFiled 16 NOV 2026
11
CLDI
CALIDI BIOTHERAPEUTICS, INC.
13G10.0%1.1MFiled 15 MAY 2026
12
VRAX
Virax Biolabs Group Ltd
13G10.0%824KFiled 17 FEB 2026
13
QUCY
MAINZ BIOMED N.V.
13G10.0%723KFiled 14 AUG 2025
14
FBLG
FibroBiologics, Inc.
13G10.0%666KFiled 16 NOV 2026
15
WLDS
Wearable Devices Ltd.
13G10.0% · 2 classes620KFiled 17 FEB 2026
16
CODX
CO-DIAGNOSTICS, INC.
13G10.0%560KFiled 14 AUG 2026
17
EDBL
Edible Garden AG Inc
13G10.0%544KFiled 17 FEB 2026
18
CYTOF
Altamira Therapeutics Ltd.
13G10.0%474KFiled 15 MAY 2025
19
ENVB
Enveric Biosciences, Inc.
13G10.0%405KFiled 14 AUG 2026
20
—
STRYVE FOODS, INC.
13G10.0% · 2 classes397KFiled 16 NOV 2026
21
CYCU
Cycurion, Inc.
13G10.0%301KFiled 17 FEB 2026
22
BDRX
Biodexa Pharmaceuticals Plc
13G10.0% · 2 classes284KFiled 17 FEB 2026
23
HCWB
HCW Biologics Inc.
13G10.0%248KFiled 16 NOV 2026
24
BJDX
Bluejay Diagnostics, Inc.
13G10.0% · 2 classes194KFiled 18 FEB 2026
25
XAIR
Beyond Air, Inc.
13G10.0%173KFiled 16 NOV 2026

Showing 1–25 of 46 disclosed stakes. 4 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Armistice Capital, LLC’s 13F portfolio

Armistice Capital, LLC’s $3.6B 13F book is spread across 323 reported positions and is moderately diversified, the ten largest names accounting for 27%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are MDGL, SUPN, CYTK, INCY and NBIX, led by MADRIGAL PHARMACEUTICALS INC (MDGL) at 4.3% of the portfolio. The heaviest sector exposure is Healthcare (68%), then Technology (15%).

What Armistice Capital, LLC changed last quarter

Between 2026-03-31 and Q2 2026, Armistice Capital, LLC was a net buyer: it opened 169 new positions and added to 70 more, while trimming 64 and closing 97 outright. Against a 323-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was MADRIGAL PHARMACEUTICALS INC (MDGL), and its biggest reduction was NEUROCRINE BIOSCIENCES INC (NBIX).

What a 13F does and doesn’t reveal

A 13F captures only Armistice Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Armistice Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Armistice Capital, LLC's profile on this page is built directly from those filings.

How current is the 13F data on Armistice Capital, LLC's page?

It reflects Armistice Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Armistice Capital, LLC files its next quarterly report, this page refreshes automatically.

Can I see Armistice Capital, LLC's complete list of holdings?

This page highlights Armistice Capital, LLC's largest positions rather than all 323 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Armistice Capital, LLC's filings.

Does a 13F show everything Armistice Capital, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Armistice Capital, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Armistice Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.